0
2019
Cystic Fibrosis (cf) Therapeutics Market

Cystic Fibrosis (CF) Therapeutics Market

by Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, and CFTR Modulators) and Route of Administration (Oral and Inhaled): Global Opportunity Analysis and Industry Forecast, 2019-2026
Update Available On-Demand

Report Code: A05134
Pages: 187
Nov 2019 | 7663 Views
Author(s) : Kavita Joshi , Onkar Sumant
Tables: 143
Charts: 37
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cystic Fibrosis (cf) Therapeutics Market

Request Now !

Cystic Fibrosis Therapeutics Market Outlook - 2026

The global cystic fibrosis therapeutics market size was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. 

Cystic fibrosis is a hereditary disorder, which majorly affects lungs and other body parts such as pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is located in chromosome number 7, and is responsible for the regulation of sweat, mucus, and body secretions. However, mutation of this gene leads to absence of CFTR activity, which in turn results in loss of chloride and alters the protein structure. Patients experience difficulty in breathing, mucus formation, fatty stool, and difficulty in the passageway of the pancreas, bile duct, intestine, & salivary gland. Cystic fibrosis is diagnosed by the use of sweat test and genetic testing. Physical therapy is used for the treatment of cystic fibrosis that helps in the reduction of mucus formation and fights against infections of an organ. In addition, treatment of cystic fibrosis includes the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation. 

Cystic Fibrosis Therapeutics Market

The global cystic fibrosis therapeutics market is expected to witness significant growth during the forecast period majorly due to availability of personalized drug therapy & molecular prosthetics for the treatment of cystic fibrosis. Furthermore, rise in prevalence of cystic fibrosis and surge in awareness about cystic fibrosis across the globe boost the cystic fibrosis market trend. For instance, according to the Cystic Fibrosis Foundation Patient Registry, in the U.S. more than 30,000 people are living with cystic fibrosis and more than 70,000 worldwide. In addition, approximately 1,000 new cases of CF are diagnosed each year and more than 75 % of people with CF are diagnosed by age 2. Moreover, increase in R&D investments made by government in the healthcare sector drives the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Developing nations such as countries of Asia-Pacific region are not so aware reading the cystic fibrosis diagnosis of the newborns. Further, in various countries, new born are not tested for CF during birth and national registries are lacking in data, thereby hampering the cystic fibrosis market growth. On the contrary, the introduction of various new drugs with better productivity and development of the healthcare R&D facilities are expected to create lucrative opportunities in the cystic fibrosis therapeutics market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.

Global Cystic Fibrosis Therapeutics Market Segmentation

The global cystic fibrosis therapeutic market is segmented on the basis of drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. By top selling drug, the market is segregated into pulmozyme, Creon, kalydeco, cayston, azithromycin, tobramycin and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Drug Class segment review

Based on cystic fibrosis therapeutics market analysis, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to increased usage of these drugs for the treatment of cystic fibrosis. This segment is also estimated to grow at the fastest rate during the forecast period. Further, the introduction of CFTR drugs, Kalydeco, Orkambi and Symdeko is one such innovation. These drugs are now widely being used for the treatment of cystic fibrosis and many other CFTR drugs are under clinical trials. The main target of these drugs is to increase the life expectancy of the patients. Moreover, advances in the diagnosis and therapeutics has significantly increased the survival of patients.

Cystic Fibrosis (CF) Therapeutics Market
By Drug Class

Your browser does not support the canvas element.

CFTR modulators segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Route of Administration segment review

By route of administration, the oral segment accounted for the majority of the cystic fibrosis therapeutics market share in 2018, owing to the increased formulation of drugs in oral form; for example, development of CFTR drugs. Further, there are currently three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets. These include ivacaftor (kalydeco), orkambi, and symdeko. The market for these oral drugs is anticipated to grow at a fast pace owing to ongoing clinical trials and research & development toward the development of oral CFTR drugs.

Cystic Fibrosis (CF) Therapeutics Market
By Route Of Administration

Your browser does not support the canvas element.

Oral route of administration is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Europe constitutes the highest market share in the global cystic fibrosis therapeutics market in 2018, followed by North America owing to the increase in incidence of cystic fibrosis. Moreover, increase in governmental support for innovation and rise in funding of projects for R&D of various cystic fibrosis drugs further fuel the market growth in this region. UK is the highest revenue contributor due to increase in prevalence of cystic fibrosis in this region. Moreover, surge in national newborn screening program in the UK propels the market growth. In addition, many companies are involved in developing drugs for individuals who do not get benefitted with CFTR drugs. However, North America is projected to grow at the highest CAGR during the forecast period.

Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.

Cystic Fibrosis (CF) Therapeutics Market
By Region

2026
Europe 
North America
Asia-pacific
Lamea

North America region would exhibit the highest CAGR of 9.9% during 2019-2026.

Get more information on this report : Request Sample Pages

Key Benefits for Cystic Fibrosis Therapeutics Market :

  • The cystic fibrosis therapeutics market share is based on a comprehensive analysis of key developments in the cystic fibrosis industry.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global cystic fibrosis therapeutics market.
  • The cystic fibrosis therapeutics market trends are studied from 2018 to 2026.
  • Information about key drivers, restrains, and opportunities and their impact analysis on the cystic fibrosis therapeutics market size is provided.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
  • The quantitative analysis of the global cystic fibrosis therapeutics market forecast from 2019 to 2026 is provided to determine the market potential.

Cystic Fibrosis (CF) Therapeutics Market Report Highlights

Aspects Details
By Drug Class
  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • CFTR modulators
By Route Of Administration
  • Oral
  • Inhaled
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, UK, France, Rest of Europe)
  • Asia Pacific  (Japan, China, India, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players F. Hoffmann-La Roche AG, Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Allergan plc, Pharmaxis Ltd, Mylan N.V
 

Loading Table Of Content...


 
 

According to CXOs, cystic fibrosis is a genetic disease that primarily affects the lungs and digestive system, but it can result in lethal disorders such as liver disease and diabetes. Symptoms of cystic fibrosis includes salty-tasting skin, persistent coughing, frequent lung infections including pneumonia or bronchitis, wheezing or shortness of breath, poor growth or weight gain in spite of a good appetite, frequent greasy, bulky stools or difficulty with bowel movements, and infertility. However, cystic fibrosis needs daily care, patients with the condition often have a better quality of life than people with cystic fibrosis had in previous decades. Improvements in treatments against cystic fibrosis has led people to live an increased lifespan.

The cystic fibrosis therapeutics market is expected to witness a substantial growth owing to the surge in incidence of cystic fibrosis. For instance, the disease affects around 30,000 people in the U.S. with around 1,000 new cases diagnosed each year. Of these new diagnoses, 75% are in children under the age of 2 years. Thereby, the U.S. government has made screening of cystic fibrosis compulsory for new born. There have been remarkable advancements in the field of cystic fibrosis treatment and the key market players are focusing toward the development of personalized drug therapy that is anticipated to propel the market growth in near future.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Cystic Fibrosis (cf) Therapeutics Market

Start reading instantly.
This Report and over 18,777+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Nov 2020 - Nov 2021)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2020 - Nov 2021)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2020 - Nov 2021)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2020 - Nov 2021)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Nov 2020 - Nov 2021)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers